Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Amplification using CHO cell expression vectors.

Kingston RE, Kaufman RJ, Bebbington CR, Rolfe MR.

Curr Protoc Mol Biol. 2002 Nov;Chapter 16:Unit 16.23. doi: 10.1002/0471142727.mb1623s60.

PMID:
18265304
2.

The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells.

Pogue SL, Preston BT, Stalder J, Bebbington CR, Cardarelli PM.

J Interferon Cytokine Res. 2004 Feb;24(2):131-9.

PMID:
14980077
3.

CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.

Pan C, Cardarelli PM, Nieder MH, Pickford LB, Gangwar S, King DJ, Yarranton GT, Buckman D, Roscoe W, Zhou F, Salles A, Chen TH, Horgan K, Wang YH, Nguyen T, Bebbington CR.

Cancer Res. 2003 Sep 1;63(17):5526-31.

4.

Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.

Finney HM, Lawson AD, Bebbington CR, Weir AN.

J Immunol. 1998 Sep 15;161(6):2791-7.

5.

Distinct intracellular localization of Lck and Fyn protein tyrosine kinases in human T lymphocytes.

Ley SC, Marsh M, Bebbington CR, Proudfoot K, Jordan P.

J Cell Biol. 1994 May;125(3):639-49.

6.

Genetic stability and product consistency of rDNA-derived biologicals from mammalian cells.

Bebbington CR, Lambert K.

Dev Biol Stand. 1994;83:183-4. No abstract available.

PMID:
7883094
7.

Selecting and designing cell lines for improved physiological characteristics.

Birch JR, Boraston RC, Metcalfe H, Brown ME, Bebbington CR, Field RP.

Cytotechnology. 1994;15(1-3):11-6.

PMID:
7765922
8.

Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture.

Bender E, Woof JM, Atkin JD, Barker MD, Bebbington CR, Burton DR.

Hum Antibodies Hybridomas. 1993 Apr;4(2):74-9.

PMID:
8518367
9.

High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker.

Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT.

Biotechnology (N Y). 1992 Feb;10(2):169-75.

PMID:
1369477
10.

The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines.

Cockett MI, Bebbington CR, Yarranton GT.

Nucleic Acids Res. 1991 Jan 25;19(2):319-25.

11.
12.

Drosophila larval fat body surfaces : Changes in transplant compatibility during development.

Rizki RM, Rizki TM, Bebbington CR, Roberts DB.

Wilehm Roux Arch Dev Biol. 1983 Jan;192(1):1-7. doi: 10.1007/BF00848762.

13.

Monoclonal antibodies recognizing cell surface antigens in Drosophila melanogaster.

Spragg JH, Bebbington CR, Roberts DB.

Dev Biol. 1982 Feb;89(2):339-52. No abstract available.

PMID:
6799344

Supplemental Content

Loading ...
Support Center